Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 4:9:958670.
doi: 10.3389/fmed.2022.958670. eCollection 2022.

Sex differences in comorbidities associated with Sjögren's disease

Katelyn A Bruno  1   2   3 , Andrea Carolina Morales-Lara  1 , Edsel B Bittencourt  4 , Habeeba Siddiqui  5 , Gabriella Bommarito  1 , Jenil Patel  1 , John M Sousou  1 , Gary R Salomon  1 , Rinald Paloka  1 , Shelby T Watford  1 , David O Hodge  5 , Scott M Lieberman  6 , Todd D Rozen  7 , Paldeep S Atwal  8 , Peter T Dorsher  9 , Lynsey A Seim  10 , DeLisa Fairweather  1   2   3   11
Affiliations

Sex differences in comorbidities associated with Sjögren's disease

Katelyn A Bruno et al. Front Med (Lausanne). .

Abstract

Background: Little is known about the association of comorbidities with sex and age at diagnosis in Sjögren's disease. We tested the hypothesis that sex differences occur in comorbidities in patients with Sjögren's disease.

Methods: Patients with Sjögren's disease were identified from 11/1974 to 7/2018 in the Mayo Clinic electronic medical record and assessed for 22 comorbidities according to sex and age at diagnosis.

Results: Of the 13,849 patients identified with Sjögren's disease, 11,969 (86%) were women and 1,880 (14%) men, primarily white (88%) with a sex ratio of 6.4:1 women to men. The mean age at diagnosis was 57 years for women and 59.7 years for men, and 5.6% had a diagnosis of fibromyalgia at Sjögren's diagnosis. Men with Sjögren's disease were more likely than women to be a current or past smoker. The average time to diagnosis of comorbidities after diagnosis of Sjögren's disease was 2.6 years. The top comorbidities in patients with Sjögren's disease were fibromyalgia (25%), depression (21.2%) and pain (16.4%). Comorbidities that occurred more often in women were hypermobile syndromes (31:1), CREST (29:1), migraine (23:1), Ehlers-Danlos syndrome (EDS) (22:1), Raynaud's syndrome (15:1), SLE (13:1), systemic sclerosis (SSc) (13:1), and fibromyalgia (12:1). Women with Sjögren's disease were at increased risk of developing hypermobile syndromes (RR 7.27, CI 1.00-52.71, p = 0.05), EDS (RR 4.43, CI 1.08-18.14, p = 0.039), CREST (RR 4.24, CI 1.56-11.50, p = 0.005), migraine (RR 3.67, CI 2.39-5.62, p < 0.001), fibromyalgia (RR 2.26, CI 1.92-2.66, p < 0.001), Raynaud's syndrome (RR 2.29, CI 1.77-2.96, p < 0.001), SLE (RR 2.13, CI 1.64-2.76, p < 0.001), and SSc (RR 2.05 CI 1.44-2.92; p < 0.001). In contrast, men with Sjögren's were at increased risk for developing myocardial infarction (RR 0.44, CI 0.35-0.55, p < 0.001), atherosclerosis/CAD (RR 0.44, CI 0.39-0.49, p < 0.001), cardiomyopathy (RR 0.63, CI 0.46-0.86, p = 0.003), stroke (RR 0.66 CI 0.51-0.85, p = 0.001), and congestive heart failure (RR 0.70, CI 0.57-0.85, p < 0.001).

Conclusions: The top comorbidities in Sjögren's disease were fibromyalgia, depression, and pain. Women with Sjögren's disease had a higher relative risk of developing fibromyalgia, depression, pain, migraine, hypermobile syndrome, EDS and other rheumatic autoimmune diseases. Men with Sjögren's disease had higher risk of developing cardiovascular diseases.

Keywords: Ehlers-Danlos syndrome; atherosclerosis; depression; fibromyalgia; hypermobile syndrome; migraine; pain; smoking.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Relative risk (hazard ratio) of comorbidities in patients with Sjögren's disease (n = 13,849). (A) Rheumatic autoimmune diseases/syndromes, (B) cardiovascular diseases, (C) pain-related conditions; pink indicates increased risk in women, blue increased risk in men.
See this image and copyright information in PMC

References

    1. Baer AN, Hammitt KM. Sjögren's disease, not syndrome. Arthr Rheumatol. (2021) 73:1347–8. 10.1002/art.41676 - DOI - PubMed
    1. Chiorini JA, Cihakova D, Ouellette CE, Caturegli P. Sjögren syndrome: advances in the pathogenesis from animal models. J Autoimmun. (2009) 33:190–6. 10.1016/j.jaut.2009.09.009 - DOI - PMC - PubMed
    1. Maciel G, Crowson CS, Matteson EL, Cornec D. Prevalence of primary Sjögren's syndrome in a US population-based cohort. Arthr Care Res. (2017) 69:1612–6. 10.1002/acr.23173 - DOI - PMC - PubMed
    1. Setoodeh K, Wallace D. Who develops Sjögren's? In: Wallace D. editor. The Sjögren's Book. New York, NY: Oxford University Press. (2012). p. 11–4.
    1. Anaya JM, Rojas-Villarraga A, Mantilla RD, Arcos-Burgos M, Sarmiento-Monroy JC. Polyautoimmunity in Sjögren syndrome. Rheum Dis Clin North Am. (2016) 42:457–72. 10.1016/j.rdc.2016.03.005 - DOI - PubMed